Literature DB >> 28337751

A novel network analysis tool to identify relationships between disease states and risks for red blood cell alloimmunization.

R Celli1, W Schulz1, J E Hendrickson1,2, C A Tormey1,3.   

Abstract

We hypothesized that diagnoses may be associated with alloantibody 'responder' status and examined associations between disease states and alloimmunization. Patients with ≥1 alloantibody and non-alloimmunized controls were analysed. Pearson's coefficients were calculated to determine associations between alloimmunization and diseases; significant correlations were selected to construct a network. Inflammatory disorders and diseases requiring chronic transfusion support were associated with responder status. Mitigation steps may be considered in patients with these disorders. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  RBC antibodies; alloimmunization; immunohaematology

Mesh:

Substances:

Year:  2017        PMID: 28337751     DOI: 10.1111/vox.12515

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  3 in total

Review 1.  Transfusion-related red blood cell alloantibodies: induction and consequences.

Authors:  Christopher A Tormey; Jeanne E Hendrickson
Journal:  Blood       Date:  2019-02-26       Impact factor: 22.113

2.  Marginal Zone B Cells Induce Alloantibody Formation Following RBC Transfusion.

Authors:  Seema R Patel; David R Gibb; Kathryn Girard-Pierce; Xiaoxi Zhou; Lilian Cataldi Rodrigues; Connie M Arthur; Ashley L Bennett; Ryan P Jajosky; Megan Fuller; Cheryl L Maier; Patricia E Zerra; Satheesh Chonat; Nicole H Smith; Christopher A Tormey; Jeanne E Hendrickson; Sean R Stowell
Journal:  Front Immunol       Date:  2018-11-16       Impact factor: 7.561

3.  Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction.

Authors:  Jeanne E Hendrickson
Journal:  Ann Blood       Date:  2020-12-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.